Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Camrelizumab - Jiangsu Hengrui Medicine

Next Previous
X
Search
Drug Profile

Camrelizumab - Jiangsu Hengrui Medicine

Alternative Names: AiRuiKa; Carbarizumab; Carrizumab; HR-301210; INCSHR-1210; SHR 1210; SHR01210

Latest Information Update: 30 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Chinese PLA General Hospital; CrystalGenomics; Fudan University; Fudan University Shanghai Cancer Center; Guangzhou Institute of Respiratory Disease; Hangzhou Cancer Hospital; Henan Cancer Hospital; Incyte Corporation; Jiangsu Hengrui Medicine Co.; Nanjing Medical University; Peking University People's Hospital; Sun Yat-Sen University; Suzhou Suncadia Biopharmaceuticals; Tianjin Medical University Cancer Institute and Hospital; West China Hospital Sichuan University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hodgkin's disease; Liver cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer
  • Phase III Cervical cancer; Gastric cancer; Triple negative breast cancer
  • Phase II Acral lentiginous melanoma; Biliary cancer; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastrointestinal cancer; Glioblastoma; HER2 negative breast cancer; Lung cancer; Malignant fibrous histiocytoma; Malignant melanoma; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer; Urogenital cancer; Uterine cancer
  • Phase I/II Bladder cancer; Diffuse large B cell lymphoma

Most Recent Events

  • 23 Sep 2024 Elevar Therapeutics resubmits a New Drug Application (NDA) to the US FDA for rivoceranib in combination with camrelizumab as a first-line systemic treatment option for unresectable Hepatocellular carcinoma (uHCC)
  • 18 Sep 2024 Camrelizumab - Jiangsu Hengrui Medicine receives Orphan Drug status for Liver cancer in European Union
  • 31 Jul 2024 Elevar Therapeutics completes a Type-A meeting with the US FDA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top